Chadha Awalpreet S, Khoo Allison, Aliru Maureen L, Arora Harpreet K, Gunther Jillian R, Krishnan Sunil
Department of Radiation Oncology, The University of Texas MD Anderson Cancer, Houston, TX.
Department of Internal Medicine, Christian Medical College, Vellore, India.
Semin Radiat Oncol. 2016 Oct;26(4):320-37. doi: 10.1016/j.semradonc.2016.05.002. Epub 2016 May 26.
The outcomes for treatment of pancreatic cancer have not improved dramatically in many decades. However, the recent promising results with combination chemotherapy regimens for metastatic disease increase optimism for future treatments. With greater control of overt or occult metastatic disease, there will likely be an expanding role for local treatment modalities, especially given that nearly a third of pancreatic cancer patients have locally destructive disease without distant metastatic disease at the time of death. Technical advances have allowed for the safe delivery of dose-escalated radiation therapy, which can then be combined with chemotherapy, targeted agents, immunotherapy, and nanoparticulate drug delivery techniques to produce novel and improved synergistic effects. Here we discuss recent advances and future directions for multimodality therapy in pancreatic cancer.
几十年来，胰腺癌的治疗效果并未显著改善。然而，近期针对转移性疾病的联合化疗方案取得了令人鼓舞的结果，这让人们对未来的治疗前景更加乐观。随着对显性或隐匿性转移性疾病的控制能力增强，局部治疗方式可能会发挥更大的作用，特别是考虑到近三分之一的胰腺癌患者在死亡时存在局部侵袭性疾病但无远处转移。技术进步使得剂量递增的放射治疗能够安全实施，随后可与化疗、靶向药物、免疫疗法以及纳米颗粒药物递送技术相结合，以产生新颖且更佳的协同效应。在此，我们将讨论胰腺癌多模态治疗的最新进展和未来方向。
